Complement Deficiencies

Complement deficiencies are inherited or acquired disorders resulting from quantitative or qualitative abnormalities in one or more components of the complement cascade, a critical system of >30 plasma and membrane proteins that amplify inflammatory responses and facilitate pathogen elimination. These deficiencies represent a primary immunodeficiency that predisposes patients to recurrent infections, autoimmune disease, and in certain deficiencies, meningococcal sepsis and angioedema. Primary complement deficiencies are rare, with prevalence ranging from 1 in 10,000 for C3 deficiency to 1 in 1,000,000 for early classical pathway deficiencies, though secondary deficiencies occur with higher frequency in systemic lupus erythematosus (SLE), post-infectious glomerulonephritis, and severe infections. The clinical significance is substantial: C1 inhibitor (C1-INH) deficiency causes hereditary angioedema (HAE), while terminal complement component deficiencies (C5-C9) carry a dramatically elevated risk of meningococcal and gonococcal infections—a critical board concept. Understanding complement deficiencies is essential for USMLE Step 2 CK because these conditions present with classic clinical patterns that can be rapidly life-threatening, require specific immunizations, and serve as high-yield exam questions often testing pattern recognition and knowledge of prophylactic management.

The complement system functions as a tripartite cascade of immune activation, with three distinct activation pathways (classical, alternative, and lectin-binding) all converging on C3 activation, which then propagates through C5-C9 to form the membrane attack complex (MAC). Understanding how defects at different points in this cascade produce distinct clinical phenotypes requires appreciation of the non-redundant functions each component serves.

The classical pathway, initiated by immunoglobulin-mediated binding to C1q or by direct pathogen recognition, serves two critical non-redundant functions: (1) opsonization and clearance of immune complexes, and (2) generation of C3a and C5a anaphylatoxins for inflammation. Deficiency of C1q, C1r, or C1s (all components of the C1 complex) results in profound inability to activate the classical cascade; this pathophysiology is particularly important for boards because C1q deficiency presents in >90% of cases with lupus-like autoimmune disease, despite technically normal C3 and C4 levels during flares. The mechanism underlying this paradox involves accumulation of immune complexes in tissues and circulation (they cannot be efficiently cleared without complement-mediated complement receptor-1 [CR1]-dependent binding and removal); these trapped complexes activate resident immune cells and endothelium, driving inflammation and tissue damage. C2 deficiency, the most common classical pathway deficiency (1 in 10,000 individuals, with ~40% of carriers having no clinical symptoms), similarly impairs immune complex clearance but paradoxically presents with either recurrent sinopulmonary infections or autoimmune disease (particularly SLE-like illness with low C4 during flares); the clinical heterogeneity reflects variable genetic modifiers and undefined factors determining which patients develop immune dysregulation. C4 deficiency (either C4A or C4B) is associated with increased risk of SLE and other autoimmune conditions, possibly due to the role of C4 in regulating B cell tolerance and in processing apoptotic debris; dysregulation of these processes predisposes to autoimmunity.

C3 deficiency represents perhaps the most severe complement immunodeficiency, as C3 is the central convergence point where all three activation pathways meet and serve as the amplification step for the entire cascade. Patients with C3 deficiency lack the ability to generate C3b (the opsonin that tags pathogens for destruction), C3a (an anaphylatoxin), and critically cannot progress to C5-C9-mediated MAC formation. The pathophysiology produces a profound immunodeficiency phenotype: patients manifest severe, recurrent infections with encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis), particularly affecting the sinopulmonary tract and meninges. Additionally, C3 deficiency commonly presents with post-infectious glomerulonephritis and membranoproliferative glomerulonephritis (MPGN) due to deposition of C3-rich but immunoglobulin-poor complexes in the glomerular basement membrane—a specific finding sometimes called "C3 glomerulopathy" when occurring in the context of dysregulation of alternative pathway regulation (Factor H or Factor I mutations). The mechanism of glomerulonephritis relates to either impaired renal clearance of immune complexes or in situ complement activation with uncontrolled alternative pathway amplification.

The alternative pathway (AP) provides continuous low-level complement activation through "tickover" of C3 and serves as the amplification loop for all complement activation; it is tightly regulated by soluble factors Factor H (CFH) and Factor I (CFI) and membrane-bound regulators including CD55 (decay-accelerating factor, DAF) and CD46 (membrane cofactor protein, MCP). Deficiency or dysfunction of Factor H (either quantitative deficiency from mutations in CFH gene or functional deficiency from mutations in complement factor H-related proteins CFHR1-5) causes uncontrolled alternative pathway activation because the main negative regulator is absent or dysfunctional; this leads to constant C3 activation, C3 deposition in kidneys and other tissues, and consumption of C3 (low serum levels). The pathophysiology directly drives atypical hemolytic uremic syndrome (aHUS) with thrombotic microangiopathy and acute kidney injury, and C3 glomerulopathy with MPGN. Factor I deficiency similarly removes a critical regulatory brake on alternative pathway activation (Factor I cleaves C3b and C4b, preventing further amplification), resulting in similar patterns of disease. Properdin deficiency (rare, X-linked) causes selective impairment of alternative pathway amplification since properdin stabilizes C3 and C5 convertases; patients present with meningococcal infections and SLE-like autoimmunity. The dysregulated complement activation in alternative pathway defects produces tissue damage through two mechanisms: (1) direct deposition of complement components in tissues causing inflammation, and (2) generation of anaphylatoxins C3a and C5a with excessive recruitment of neutrophils and other inflammatory cells to sites of activation.

Deficiency of any terminal complement component (C5, C6, C7, C8, or C9) prevents formation of the membrane attack complex (MAC, C5b-9), which creates osmotic lysis pores in pathogen membranes. This pathway is non-redundant for killing certain organisms, particularly Neisseria meningitidis and Neisseria gonorrhoeae, organisms with relatively thin cell walls that lack robust alternative defenses and are exquisitely susceptible to complement-mediated lysis. The pathophysiology explains the striking epidemiologic finding that patients with C5-C9 deficiencies have a 100-fold to 1,000-fold increased risk of meningococcal infection compared to the general population; this is a classic board fact. Notably, C9 deficiency is the most common terminal pathway deficiency and paradoxically carries lower infection risk than other terminal pathway deficiencies, possibly because C5b-8 complex alone can form some lytic pores, and because complement-dependent antibody and cell-mediated killing pathways can partially compensate. Patients with terminal pathway defects still maintain C3-dependent opsonization and anaphylatoxin generation, explaining why they have normal resistance to most other organisms but selective vulnerability to meningococci.

C1-Inhibitor (C1-INH) is a serine protease inhibitor that regulates not only classical complement pathway activation (inhibiting C1r and C1s) but also the contact system (inhibiting Hageman factor, also called Factor XII, and kallikrein). Deficiency of C1-INH, either quantitative (Type 1 HAE, ~85% of cases) or qualitative (Type 2 HAE, ~15% of cases with normal or elevated C1-INH levels but dysfunctional protein), results in uncontrolled activation of Factor XII leading to excessive bradykinin generation from high-molecular-weight kininogen (HMWK). Bradykinin is a potent vasodilator and increases vascular permeability, causing localized edema in the dermis and submucosa; importantly, this represents a non-histamine-mediated angioedema (thus unresponsive to antihistamines and corticosteroids, a critical board concept), and the edema characteristically does not itch or cause urticaria. The pathophysiology also produces a pro-thrombotic state due to dysregulation of the contact system, explaining increased thrombotic risk in some C1-INH-deficient patients. Recent literature has identified Type 3 HAE with normal C1-INH function and normal C4 levels but mutations in genes encoding Factor XII, plasminogen, or angiotensin-converting enzyme (ACE), underscoring ongoing expansion of understanding of pathways regulating bradykinin generation.

Complement deficiencies are classified as primary (inherited, usually autosomal recessive, though properdin deficiency is X-linked) or secondary (acquired due to consumption or impaired synthesis in systemic disease).

Classical pathway gene deficiencies (C1q, C1r, C1s, C2, C4) are inherited in autosomal recessive patterns with generally complete penetrance, though clinical expressivity varies widely; for example, C2 deficiency affects 1 in 10,000 individuals but only a fraction develops symptoms, suggesting genetic modifiers influence phenotype. C1-INH deficiency causing hereditary angioedema is autosomal dominant with 25% new mutations, making family history absent in approximately one-quarter of cases (important for students to recognize that negative family history does not exclude diagnosis). Alternative pathway deficiencies including Factor H deficiency, Factor I deficiency, and properdin deficiency are inherited in autosomal recessive (Factor H and I) or X-linked (properdin) patterns; mutations in complement factor H-related genes (CFHR1, CFHR3, etc.) are associated with C3 glomerulopathy and aHUS due to loss of Factor H regulatory function. Terminal complement pathway deficiencies (C5-C9) show autosomal recessive inheritance; notably, heterozygous carriers of C5-C9 deficiencies typically remain asymptomatic, as one functional allele maintains adequate MAC formation capacity. C3 deficiency is autosomal recessive; mutations in C3 gene itself account for only a minority of cases, with most C3-deficient patients having mutations in regulatory genes (Factor H, Factor I, or C3 nephritic factors), underscoring the importance of complement regulation in maintaining appropriate C3 levels.

Systemic lupus erythematosus (SLE) is the prototypical condition causing acquired C3 and C4 consumption; SLE patients develop anti-C1q antibodies and form immune complexes that activate classical pathway, resulting in low C3 and C4 levels that correlate with disease activity and nephritis risk. Post-infectious glomerulonephritis, particularly post-streptococcal glomerulonephritis and endocarditis-related MPGN, causes transient C3 and C4 consumption as immune complexes deposit in glomeruli. Severe infections (sepsis, meningococcemia) cause rapid complement consumption through massive pathway activation, producing progressively lower C3 and C4 levels that carry prognostic significance. Membranoproliferative glomerulonephritis with C3 deposition (C3GN) caused by Factor H dysfunction or circulating C3 nephritic factors leads to chronic alternative pathway dysregulation and C3 consumption. Liver disease produces secondary complement deficiency through impaired hepatic synthesis of complement components and regulatory proteins. Nephrotic syndrome causes loss of complement proteins (particularly C3, Factor H, and other regulators) through proteinuria, potentially unmasking subclinical Factor H dysfunction or creating acquired-like Factor H deficiency. Malignancy, particularly lymphoproliferative diseases, can cause acquired C1-INH deficiency through production of proteases that cleave C1-INH, causing acquired angioedema (Type 2 acquired HAE).

Asplenia (surgical or functional) significantly elevates infection risk in complement-deficient patients, particularly those with defects in opsonization (classical pathway or C3 deficiency), requiring combined meningococcal and pneumococcal vaccination strategies. **Exposure to *Neisseria meningitidis* is a critical risk factor in terminal pathway-deficient individuals; close contacts (household, dormitory, military) and crowded settings increase risk dramatically. Prophylactic antimicrobial exposure is paradoxically a risk factor because it selects for resistance in chronic colonization, and antimicrobial prophylaxis may be less effective in preventing breakthrough infections in complement-deficient patients. Immunoglobulin deficiency (primary or secondary) compounded on complement deficiency dramatically worsens infection risk. Allergic or atopic disease** can be a risk factor for mast cell degranulation and anaphylaxis in patients with complement activation from infections or triggers, potentially confusing the clinical picture.

The clinical manifestations of complement deficiencies vary dramatically depending on which component(s) are deficient, reflecting the non-redundant functions of different complement pathways and components.

Classical pathway and C3 deficiency present with recurrent infections by encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Streptococcus pyogenes) affecting sinuses, lungs, ears, and meninges; patients characteristically have histories of sinusitis, otitis media, pneumonia, and meningitis starting in early childhood and continuing into adulthood if untreated. The mechanism reflects impaired C3b-dependent opsonization—complement-coated bacteria are poor substrates for antibody-mediated phagocytosis and lack the full complement-receptor-mediated enhancement of killing. Terminal pathway deficiency (C5-C9) produces a more selective pattern: meningococcal disease is the most common serious infection, often recurrent (particularly unusual since meningococcal disease typically confers lifelong immunity, making recurrent meningococcal infections a hallmark finding in terminal pathway deficiency), and gonococcal infection (particularly disseminated gonococcemia) is strikingly common; other gram-negative organisms and typical community-acquired pathogens are handled normally. The selective vulnerability to Neisseria species reflects their unique susceptibility to MAC-mediated lysis and lack of robust alternative defenses.

Classical pathway deficiencies (C1q, C2, C4) present with lupus-like autoimmune disease in 25-75% of cases, manifesting as rash, arthritis, arthralgia, photosensitivity, and occasionally nephritis; serology typically shows positive antinuclear antibodies (ANA) and negative anti-dsDNA antibodies (distinguishing from true SLE). The mechanism reflects impaired immune complex clearance—complexes accumulate in tissues and cause inflammation. Notably, during flares of complement-mediated autoimmunity, C4 drops despite being normal at baseline, and C3 levels may remain normal (another board-testable pearl: C3 and C4 can be normal in classical pathway deficiency between episodes). C3 deficiency presents with lupus-like disease and glomerulonephritis, but the distinctive feature is post-infectious glomerulonephritis and C3 glomerulopathy with MPGN